IDEAYA Biosciences, Inc.
IDYA
$30.24
$0.391.31%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5,377.66% | -41.47% | -54.85% | -70.07% | -83.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5,377.66% | -41.47% | -54.85% | -70.07% | -83.30% |
| Cost of Revenue | 90.57% | 101.67% | 123.43% | 127.53% | 67.40% |
| Gross Profit | 18.95% | -112.51% | -144.87% | -171.07% | -105.88% |
| SG&A Expenses | 56.50% | 45.44% | 47.57% | 38.84% | 31.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.29% | 92.39% | 110.31% | 111.62% | 60.54% |
| Operating Income | 7.06% | -100.76% | -126.39% | -143.23% | -88.94% |
| Income Before Tax | 9.76% | -115.82% | -138.25% | -142.98% | -72.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.76% | -115.82% | -138.25% | -142.98% | -72.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.76% | -115.82% | -138.25% | -142.98% | -72.59% |
| EBIT | 7.06% | -100.76% | -126.39% | -143.23% | -88.94% |
| EBITDA | 7.19% | -102.12% | -128.50% | -145.98% | -90.74% |
| EPS Basic | 20.97% | -73.55% | -79.26% | -67.97% | -19.54% |
| Normalized Basic EPS | 15.94% | -71.80% | -76.90% | -66.50% | -27.69% |
| EPS Diluted | 20.24% | -73.55% | -79.26% | -67.97% | -19.54% |
| Normalized Diluted EPS | 15.24% | -71.80% | -76.90% | -66.50% | -27.69% |
| Average Basic Shares Outstanding | 15.83% | 25.88% | 32.44% | 42.08% | 43.13% |
| Average Diluted Shares Outstanding | 16.21% | 25.88% | 32.44% | 42.08% | 43.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |